Reduced-dose apixaban noninferior to full dose for cancer-associated thrombosis
1. Among patients with active cancer and prior venous thromboembolism (VTE), extended treatment with reduced-dose apixaban demonstrated noninferior efficacy to ...
Tag: VTE
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
1. Recurrent VTE occurred in 2.1% in the reduced-dose group and 2.8% in the full-dose group, with HR 0.76 (was ...
#VisualAbstract: Reduced-Dose was Not Non-Inferior to Full-Dose Direct Oral Anticoagulants in Venous Thromboembolism Patients
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Higher quantity of rib fractures may be a risk factor for venous thromboembolism
Incidence and influence factors of venous thromboembolism in traumatic rib fracture patient: a multicenter study 1. In patients with traumatic ...
Statin use may reduce risk of venous thromboembolism in women taking hormone therapy
1. In this case-control study, the use of statins in menopausal women concurrently with hormone therapy (HT) significantly reduced the ...
#VisualAbstract: Aspirin associated with significantly higher rate of symptomatic venous thromboembolism compared to enoxaparin in patients undergoing hip or knee arthroplasty
1. In this random1. In this randomized controlled trial that included 9711 patients undergoing hip or knee arthroplasty, treatment ...
#VisualAbstract: Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19
1. The primary efficacy outcome of symptomatic and asymptomatic venous thromboembolism was significantly lower in the rivaroxaban group (3.14%) compared ...
Utility of D-dimer testing and modified thresholds for ruling out pulmonary embolism in COVID-19 patients
1. The D-dimer test threshold of 0.05 µg/mL in COVID patients had a sensitivity of 100%, a specificity of 8.8%, ...
